High expression of TNFSF13 in tumor cells and fibroblasts is associated with poor prognosis in non-small cell lung cancer

American Journal of Clinical Pathology

Volumn 141, Issue 2, 2014, Pages 226-233

  Zhao, Qian ^a   Cai, Qingshan ^a   Jin, Chun ^a   Zhu, Huijun ^b   Li, Feng ^a   Wei, Qiang ^a   Xia, Qiang ^a   Zhu, Min ^a  

^a Integrated Chinese and Western Medicine Hospital of Zhejiang Province   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Non small cell lung cancer; Overall survival; Tissue microarray; Tumor necrosis factor ligand superfamily member 13 (TNFSF13)

Indexed keywords

APRIL PROTEIN; MESSENGER RNA; TNFSF13 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL; VERY ELDERLY; BIOSYNTHESIS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MORTALITY; NON-SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13 (TNFSF13);

IMMUNOHISTOCHEMISTRY; NON-SMALL CELL LUNG CANCER; OVERALL SURVIVAL; TISSUE MICROARRAY; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13 (TNFSF13);

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84895196323     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP4JP8BZOMHEAW     Document Type: Article

References (36)

1. Lin J, Beer DG. Molecular predictors of prognosis in lung cancer. Ann Surg Oncol. 2012;19:669-676.
2. Reckamp KL. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Lett. 2012;321:101-109.
3. Drilon A, Rekhtman N, Ladanyi M, et al. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012;13:e418-e426.
4. Sudhindra A, Ochoa R, Santos ES. Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. Clin Lung Cancer. 2011;12:360-368.
5. Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188:1185-1190. (Pubitemid 28443341)
6. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18:263-275. (Pubitemid 44287558)
7. Matthes T, Dunand-Sauthier I, Santiago-Raber ML, et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood. 2011;118:1838-1844.
8. Moreaux J, Veyrune JL, De Vos J, et al. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer. 2009;9:83.
9. Pelekanou V, Notas G, Theodoropoulou K, et al. Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. Anal Cell Pathol (Amst). 2011;34:49-60.
10. Pelekanou V, Kampa M, Kafousi M, et al. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer. 2008;8:76.
11. Sun B, Wang H, Wang X, et al. A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer. Exp Lung Res. 2009;35:486-500.
12. Bojarska-Junak A, Hus I, Chocholska S, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res. 2009;33:1319-1327.
13. Munari F, Lonardi S, Cassatella MA, et al. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood. 2011;117:6612-6616.
14. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell. 2004;6:399-408. (Pubitemid 39361440)
15. Salameh TS, Le TT, Nichols MB, et al. An ex vivo co-culture model system to evaluate stromal-epithelial interactions in breast cancer. Int J Cancer. 2013;132:288-296.
16. Guo M, Liu W, Serra S, et al. FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res. 2012;72:2017-2027.
17. Angelucci C, Maulucci G, Lama G, et al. Epithelial-stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness. PLoS One. 2012;7:e50804.
18. Petty RD, Samuel LM, Murray GI, et al. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer. 2009;9:434.
19. Goldstraw P. The 7th edition of TNM in Lung Cancer: what now? J Thorac Oncol. 2009;4:671-673.
20. Feng J, Zhang X, Zhu H, et al. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 2012;138:230-235.
21. Huang J, Zhang J, Li H, et al. VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am J Transl Res. 2013;5:336-346.
22. Stein JV, Lopez-Fraga M, Elustondo FA, et al. APRIL modulates B and T cell immunity. J Clin Invest. 2002;109:1587-1598. (Pubitemid 34663521)
23. Tangye SG, Bryant VL, Cuss AK, et al. BAFF, APRIL and human B cell disorders. Semin Immunol. 2006;18:305-317. (Pubitemid 44287555)
24. Kelly K, Manos E, Jensen G, et al. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res. 2000;60:1021-1027. (Pubitemid 30129540)
25. Tsao AS, Papadimitrakopoulou V. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013;14:311-321.
26. Planchard D. Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol. 2013;8:3-14.
27. Ohashi K, Sequist LV, Arcila ME, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013;19:2584-2591.
28. Giroux Leprieur E, Antoine M, Vieira T, et al. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Lung Cancer. 2013;79:167-172.
29. Ding W, Wang J, Sun B, et al. APRIL knockdown suppresses migration and invasion of human colon carcinoma cells. Clin Biochem. 2009;42:1694-1698.
30. Dai S, Zheng Y, Chen B, et al. Two Gln187 mutants of human soluble APRIL inhibit proliferation of lung carcinoma A549 cells. Acta Biochim Pol. 2009;56:703-710.
31. Mhawech-Fauceglia P, Kaya G, Sauter G, et al. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol. 2006;80:697-704. (Pubitemid 44835884)
32. Schwaller J, Schneider P, Mhawech-Fauceglia P, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood. 2007;109:331-338. (Pubitemid 46053074)
33. Kimberley FC, Hahne M, Medema JP. "APRIL hath put a spring of youth in everything": relevance of APRIL for survival. J Cell Physiol. 2009;218:1-8.
34. Yaccoby S, Pennisi A, Li X, et al. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia. 2008;22:406-413. (Pubitemid 351250547)
35. Zonca M, Mancheno-Corvo P, DelaRosa O, et al. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase. Tissue Eng Part A. 2012;18:852-859.
36. Lascano V, Zabalegui LF, Cameron K, et al. The TNF family member APRIL promotes colorectal tumorigenesis. Cell Death Differ. 2012;19:1826-1835.